2022
DOI: 10.3390/ph15121461
|View full text |Cite
|
Sign up to set email alerts
|

In Combo Studies for the Optimization of 5-Aminoanthranilic Acid Derivatives as Potential Multitarget Drugs for the Management of Metabolic Syndrome

Abstract: Metabolic syndrome is a set of risk factors that consist of abdominal obesity, arterial hypertension, alterations in the lipid profile, and hyperglycemia. The current therapeutic strategy includes polypharmacy, using three or more drugs to control each syndrome component. However, this approach has drawbacks that could lead to therapeutic failure. Multitarget drugs are molecules with the ability to act on different targets simultaneously and are an attractive alternative for treating complex diseases such as m… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 95 publications
0
2
0
Order By: Relevance
“…Several mechanisms have been proposed to explain the multiple bioactivities of MB components. The use of molecular docking + molecular dynamics simulation has been proven useful for the prediction or delimitation of the potential molecular mechanism of action of some molecules, particularly those of natural origin and in potential multitarget ligands [34][35][36][37][38][39][40][41].…”
Section: Effect Of Mb Administration On Oxidative Stress Markersmentioning
confidence: 99%
“…Several mechanisms have been proposed to explain the multiple bioactivities of MB components. The use of molecular docking + molecular dynamics simulation has been proven useful for the prediction or delimitation of the potential molecular mechanism of action of some molecules, particularly those of natural origin and in potential multitarget ligands [34][35][36][37][38][39][40][41].…”
Section: Effect Of Mb Administration On Oxidative Stress Markersmentioning
confidence: 99%
“…However, in more advanced cases, pharmacological treatment becomes necessary. 43 There is no single drug to treat MetS. The approach must be individualized, with the management of each metabolic alteration and its associated comorbidity: statins, hypoglycemic agents, antihypertensive drugs, and antiplatelet drugs for those with increased prothrombotic risk.…”
Section: Pharmacological Treatmentmentioning
confidence: 99%